非酒精性脂肪性肝病：东方与西方
Non-alcoholic Fatty Liver Disease: East Versus West.
作者信息
Agrawal Swastik, Duseja Ajay K
机构信息
Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
出版信息
J Clin Exp Hepatol. 2012 Jun;2(2):122-34. doi: 10.1016/S0973-6883(12)60101-7. Epub 2012 Jul 21.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is an important cause of liver disease worldwide with prevalence ranging from 10% to 30% in various countries. It has become an important cause of unexplained rise in transaminases, cryptogenic cirrhosis, and cryptogenic hepatocellular carcinoma. Pathogenesis is related to obesity, insulin resistance, oxidative stress, lipotoxicity, and resultant inflammation in the liver progressing to fibrosis. Pharmacological treatment in patients with NAFLD is still evolving and the treatment of these patients rests upon lifestyle modification with diet and exercise being the cornerstones of therapy. While there are many similarities between patients with NAFLD from Asia and the West, there are certain features which make the patients with NAFLD from Asia stand apart. This review highlights the data on NAFLD from Asia comparing it with the data from the West.
摘要
非酒精性脂肪性肝病（NAFLD）是全球肝脏疾病的重要病因，在各个国家的患病率从10%到30%不等。它已成为转氨酶不明原因升高、隐源性肝硬化和隐源性肝细胞癌的重要病因。发病机制与肥胖、胰岛素抵抗、氧化应激、脂毒性以及肝脏随之发生的炎症进展为纤维化有关。NAFLD患者的药物治疗仍在不断发展，这些患者的治疗依赖于生活方式的改变，饮食和运动是治疗的基石。虽然亚洲和西方的NAFLD患者有许多相似之处，但也有一些特征使亚洲的NAFLD患者有所不同。本综述重点介绍了亚洲NAFLD的数据，并与西方的数据进行了比较。
相似文献
1
Non-alcoholic Fatty Liver Disease: East Versus West.
J Clin Exp Hepatol. 2012 Jun;2(2):122-34. doi: 10.1016/S0973-6883(12)60101-7. Epub 2012 Jul 21.
2
Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology.
J Clin Exp Hepatol. 2015 Mar;5(1):51-68. doi: 10.1016/j.jceh.2015.02.006. Epub 2015 Mar 6.
3
Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Metabolism. 2013 Nov;62(11):1651-61. doi: 10.1016/j.metabol.2013.06.012. Epub 2013 Aug 5.
4
Patients with Nonalcoholic Fatty Liver Disease (NAFLD) have Higher Oxidative Stress in Comparison to Chronic Viral Hepatitis.
J Clin Exp Hepatol. 2013 Mar;3(1):12-8. doi: 10.1016/j.jceh.2012.10.009. Epub 2012 Nov 2.
5
Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis.
J Clin Exp Hepatol. 2012 Jun;2(2):156-73. doi: 10.1016/S0973-6883(12)60104-2. Epub 2012 Jul 21.
6
Mechanism of the development of nonalcoholic steatohepatitis after pancreaticoduodenectomy.
BBA Clin. 2015 Feb 19;3:168-74. doi: 10.1016/j.bbacli.2015.02.001. eCollection 2015 Jun.
7
Non-Alcoholic Fatty Liver Disease.
Adv Exp Med Biol. 2017;960:443-467. doi: 10.1007/978-3-319-48382-5_19.
8
Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients.
BBA Clin. 2014 Sep 20;3:141-5. doi: 10.1016/j.bbacli.2014.09.001. eCollection 2015 Jun.
9
Magnitude of Nonalcoholic Fatty Liver Disease: Eastern Perspective.
J Clin Exp Hepatol. 2019 Jul-Aug;9(4):491-496. doi: 10.1016/j.jceh.2019.01.007. Epub 2019 Feb 7.
10
From sugar to liver fat and public health: systems biology driven studies in understanding non-alcoholic fatty liver disease pathogenesis.
Proc Nutr Soc. 2019 Aug;78(3):290-304. doi: 10.1017/S0029665119000570. Epub 2019 Mar 29.
引用本文的文献
1
Breaking boundaries: Unraveling metabolic dysfunction-associated steatotic liver disease in children of India and Canada.
Can Liver J. 2024 Feb 26;7(3):327-337. doi: 10.3138/canlivj-2023-0023. eCollection 2024 Aug.
2
Screening of Family Members of Nonalcoholic Fatty Liver Disease Patients can Detect Undiagnosed Nonalcoholic Fatty Liver Disease Among Them: Is There a Genetic Link?
J Clin Exp Hepatol. 2021 Jul-Aug;11(4):466-474. doi: 10.1016/j.jceh.2020.10.003. Epub 2020 Oct 10.
3
Prevalence and Clinical Characteristics of NAFLD in Chronic Liver Disease Patients from King Abdulaziz University Hospital, Jeddah.
Saudi J Med Med Sci. 2020 May-Aug;8(2):118-124. doi: 10.4103/sjmms.sjmms_272_19. Epub 2020 Apr 17.
4
Nonalcoholic Fatty Liver Disease in The Rotterdam Study: About Muscle Mass, Sarcopenia, Fat Mass, and Fat Distribution.
J Bone Miner Res. 2019 Jul;34(7):1254-1263. doi: 10.1002/jbmr.3713. Epub 2019 May 10.
5
Ethnic differences and heterogeneity in genetic and metabolic makeup contributing to nonalcoholic fatty liver disease.
Diabetes Metab Syndr Obes. 2019 Mar 19;12:357-367. doi: 10.2147/DMSO.S182331. eCollection 2019.
6
Renal Dysfunction in Patients With Nonalcoholic Fatty Liver Disease is Related to the Presence of Diabetes Mellitus and Severity of Liver Disease.
J Clin Exp Hepatol. 2019 Jan-Feb;9(1):22-28. doi: 10.1016/j.jceh.2017.12.005. Epub 2017 Dec 30.
7
Editor-in-Chief's welcome to .
Hepatol Med Policy. 2016 Apr 13;1:1. doi: 10.1186/s41124-016-0005-9. eCollection 2016.
8
A Case of Acute-on-Chronic Liver Failure (ACLF) Due to An Uncommon Acute And Chronic Event.
J Clin Exp Hepatol. 2018 Mar;8(1):95-97. doi: 10.1016/j.jceh.2017.08.006. Epub 2017 Sep 1.
9
Low-grade small intestinal bacterial overgrowth is common in patients with non-alcoholic steatohepatitis on quantitative jejunal aspirate culture.
Indian J Gastroenterol. 2017 Sep;36(5):390-399. doi: 10.1007/s12664-017-0797-6. Epub 2017 Oct 16.
10
Non-alcoholic Fatty Liver Disease in South Asians: A Review of the Literature.
J Clin Transl Hepatol. 2017 Mar 28;5(1):76-81. doi: 10.14218/JCTH.2016.00045. Epub 2017 Feb 7.
本文引用的文献
1
Risk factors of cryptogenic hepatocellular carcinoma in patients with low body mass index or without metabolic syndrome.
Korean J Intern Med. 2012 Mar;27(1):47-52. doi: 10.3904/kjim.2012.27.1.47. Epub 2012 Feb 28.
2
APOC3 and PNPLA3 in non-alcoholic fatty liver disease: need to clear the air.
J Gastroenterol Hepatol. 2012 May;27(5):848-51. doi: 10.1111/j.1440-1746.2012.07103.x.
3
A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in non-alcoholic fatty liver disease.
Hum Genet. 2012 Jul;131(7):1145-52. doi: 10.1007/s00439-012-1141-y. Epub 2012 Jan 19.
4
Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease.
Hepatology. 2012 Jan;55(1):77-85. doi: 10.1002/hep.24706. Epub 2011 Dec 6.
5
Genetic variant in PNPLA3 is associated with nonalcoholic fatty liver disease in China.
Hepatology. 2012 Jan;55(1):327-8. doi: 10.1002/hep.24659.
6
Visceral obesity modulates the impact of apolipoprotein C3 gene variants on liver fat content.
Int J Obes (Lond). 2012 Jun;36(6):774-82. doi: 10.1038/ijo.2011.154. Epub 2011 Aug 9.
7
The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver.
J Hepatol. 2011 Dec;55(6):1409-14. doi: 10.1016/j.jhep.2011.03.035. Epub 2011 Jul 21.
8
Association of PNPLA3 SNP rs738409 with liver density in African Americans with type 2 diabetes mellitus.
Diabetes Metab. 2011 Nov;37(5):452-5. doi: 10.1016/j.diabet.2011.05.001. Epub 2011 Jun 14.
9
Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease.
Hepatology. 2011 Jun;53(6):1883-94. doi: 10.1002/hep.24283. Epub 2011 May 14.
10
Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance.
Hepatology. 2011 Feb;53(2):467-74. doi: 10.1002/hep.24072. Epub 2010 Dec 10.
Zotero 插件